The March 2026 NHS England Board papers show that diagnostic performance is one of the most important constraints behind wider NHS backlog recovery.

Elective waiting lists are reducing, long waits are improving, and Referral to Treatment performance has improved year on year. But diagnostic waits are moving in the opposite direction. In January 2026, 24.7% of patients were waiting more than six weeks for a diagnostic procedure or test. That was a slight improvement from December 2025, but worse than the 22.4% reported in January 2025.

This matters because diagnostics sit at the centre of several major NHS priorities. They affect elective treatment decisions, cancer diagnosis, clinical prioritisation, outpatient flow, patient safety, productivity and the ability of providers to reduce waits sustainably.

The core signal is clear: the NHS cannot secure backlog recovery unless diagnostic capacity and diagnostic flow improve alongside elective activity.

Diagnostics are not keeping pace with demand

The diagnostic signal in the Integrated Performance Report is direct. The proportion of patients waiting more than six weeks for a diagnostic test stood at 24.7% in January 2026, compared with 24.8% in December 2025 and 22.4% in January 2025. NHS England describes the year-on-year deterioration as the result of waiting-list activity growth failing to keep pace with waiting-list demand growth. Activity growth was 3.3% year to date to December 2025, compared with demand growth of 3.6%, against a 4% projection.

This is not simply a temporary operational fluctuation. It points to a structural demand-capacity mismatch. When activity growth falls behind demand growth, even marginally, the effect compounds across pathways. More patients wait longer for tests. More clinical decisions remain unresolved. More outpatient appointments risk becoming follow-ups without definitive progression. More cancer and elective pathways become exposed to delay.

The Integrated Performance Report states that NHS England has taken actions between May 2025 and March 2026 to improve diagnostic performance. These include capital investment in capacity, clinical support for Tier 1 providers, provider-level modality-specific deep dives and demand optimisation initiatives.

The important point for leaders is that these actions recognise diagnostics as a pathway problem, not just a volume problem. Capacity matters, but so do demand management, modality-level oversight, clinical thresholds, reporting reliability, workforce deployment and the operational ability to move patients quickly from test request to result and treatment decision.

Elective recovery depends on diagnostic recovery

The March Board papers show clear progress in elective care. The total elective waiting list fell to 7,247,214 in January 2026, down from 7,290,880 in December 2025 and down 180,455 compared with January 2025. The proportion of elective patients waiting less than 18 weeks improved to 61.5%, up from 58.9% a year earlier, while the proportion waiting over 52 weeks reduced to 1.87%.

Those figures show genuine recovery. But they also show why diagnostics now matter so much. Referral to Treatment performance remains below the 2025/26 requirement of 65%, and the waiting list remains very large. A system cannot reliably accelerate RTT improvement if diagnostic steps become the limiting factor.

This is especially relevant because elective recovery increasingly depends on pathway discipline. Patients need to move from referral to triage, diagnostics, diagnosis, clinical decision-making and treatment without avoidable delay. If diagnostic capacity does not keep pace, additional theatre or outpatient capacity may not translate into proportional RTT improvement.

There is also a patient-safety dimension. Delayed diagnostics can mean delayed treatment decisions, longer periods of uncertainty, later escalation and more complex care needs by the time patients are seen. The Board pack does not quantify harm arising from diagnostic delay, and it would be inappropriate to infer figures that are not presented. But the operational link between diagnostic delay and pathway risk is clear from the structure of elective and cancer standards.

The implication is that diagnostic improvement must sit inside elective recovery planning, not beside it. For provider and system leaders, diagnostic performance should be viewed as a core recovery metric, not a supporting metric.

Cancer performance shows the clinical consequence

Cancer pathways show the clearest clinical consequence of diagnostic pressure.

In January 2026, performance against the Faster Diagnosis Standard was 72.8%, down from 77.4% in December 2025 and slightly below the 73.4% reported in January 2025. NHS England describes the month-on-month fall as in line with expected seasonal trends, but the January position still remains below the ambition to exceed 80% in March 2026.

The 62-day combined cancer standard also remained under pressure. In January 2026, 68.4% of patients were treated within the 62-day cancer standard, against the 80% planning guidance ambition. This was down from 71.9% in December 2025, although slightly improved from 67.6% in January 2025.

The Board papers also show significant provider variation. For the Faster Diagnosis Standard in January 2026, provider performance ranged from 86.9% at the highest end to 39.4% at the lowest end. For the 62-day cancer standard, performance ranged from 100.0% to 47.2% across providers.

This variation matters because cancer pathway performance is not just a national average. It is experienced by patients locally, provider by provider and pathway by pathway. A patient’s ability to receive a timely diagnosis and treatment decision can depend heavily on local capacity, diagnostic access, pathway coordination and specialty-level flow.

There is also a more positive signal. The proportion of all cancers diagnosed at stage 1 or 2 was 59.7% on a 12-month average in November 2025, up from 58.2% in November 2024. NHS England links earlier diagnosis work to programmes including lung cancer screening, bowel cancer screening changes and expected publication of the NHS Cancer Plan.

The overall cancer signal is therefore mixed: earlier diagnosis is improving, but operational cancer standards remain under pressure. That makes diagnostic resilience even more important.

Productivity expectations are reshaping diagnostics

The Strategy Committee papers place diagnostics within the wider productivity agenda.

The Committee reviewed a Productivity Plan aimed at achieving 2% annual productivity growth. It identified reducing unwarranted variation as the core strategy for baseline productivity gains and highlighted more disruptive innovations, including expanded day-case surgery, scaled diagnostic models and artificial intelligence, as ways to shift the productivity frontier.

This is an important system signal. Diagnostics are not being treated only as an access problem. They are becoming part of the NHS productivity model.

That creates both opportunity and pressure. Scaled diagnostic models may improve throughput, reduce duplication and support more consistent pathways. Artificial intelligence may support workflow, reporting, triage and prioritisation where clinically appropriate and safely governed. Modality-specific deep dives may help systems understand where demand, workforce, reporting or equipment constraints are most acute.

But productivity cannot mean speed without governance. Diagnostic improvement must remain clinically safe, quality-assured and integrated with provider pathways. Faster testing is only valuable if results are accurate, acted upon and connected to timely treatment decisions.

The March Board pack also shows that financial conditions are tightening. At Month 10, the NHS was broadly in balance nationally, but systems were overspending by £428 million year to date, and 14 systems were forecasting year-end overspends.

That means diagnostic recovery will need to meet a higher value test. Investment in capacity will increasingly need to show measurable contribution to access, productivity, pathway flow, patient safety and financial discipline.

The bottleneck is operational, clinical and strategic

The diagnostic backlog is not a narrow technical issue. It is operational, clinical and strategic.

Operationally, diagnostics determine whether elective pathways move or stall. Clinically, they affect the speed and accuracy of diagnosis, treatment planning and escalation. Strategically, they influence whether the NHS can deliver elective recovery, cancer improvement and productivity gains at the same time.

The February Board minutes show that members had already noted diagnostic waits rising to nearly 22% and raised concerns about long waits in community services, paediatrics and neurodiversity assessments. The March Integrated Performance Report then shows diagnostic six-week waits at 24.7% in January 2026.

This trajectory matters. It suggests that diagnostic pressure was already visible in prior Board discussion and remained a live performance challenge in the March papers.

For provider leaders, the key question is no longer whether diagnostics need attention. It is how diagnostic recovery is linked to elective recovery, cancer pathway performance, outpatient transformation, workforce planning and financial control.

For integrated care boards, the issue is also about variation and system design. Diagnostic performance cannot be solved only within individual departments. It requires system-level understanding of referral demand, community diagnostic capacity, acute-site constraints, workforce availability, reporting backlogs, clinical prioritisation and access inequalities.

What this means now

The March Board papers show that diagnostics are a central constraint on NHS backlog recovery.

Elective waiting lists are falling, but RTT performance remains below requirement. Cancer early diagnosis is improving, but cancer standards remain below ambition. Diagnostic waits are worse year on year, with demand growth outpacing activity growth. Financial pressure means additional capacity must be targeted and productive. Productivity expectations mean diagnostic models will need to reduce variation, improve flow and support safe pathway redesign.

For patients, the diagnostic bottleneck means continued risk of delay between referral, diagnosis and treatment decision. For healthcare workers, it means operational pressure across imaging, endoscopy, pathology, outpatient clinics, cancer teams and administrative functions. For provider leaders, it means elective recovery plans are only as strong as the diagnostic pathways that support them.

The system implication is clear: backlog recovery will not become sustainable until diagnostics are planned, governed and resourced as a core delivery function rather than a downstream support service.

The next phase of NHS recovery will depend on whether systems can turn diagnostic capacity into faster, safer and more reliable clinical decision-making.

References

• NHS England, Integrated Performance Report, March 2026.
• NHS England, Month 10 financial position 2025/26, March 2026.
• NHS England, Board Committee updates – NHS England Strategy Committee, March 2026.
• NHS England, Minutes of a public meeting of the NHS England Board held on Thursday 5 February 2026, published March 2026.
• NHS England, Meeting of the Board of NHS England – agenda, 26 March 2026.